Prophylactic treatment of superficial bladder tumor

International Journal of Urology

Volumn 5, Issue 6, 1998, Pages 511-520

  Lee, Chongwook ^a,b   Park, Moon Soo ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

Bladder; Cancer; Prophylactic; Review; Superficial

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE; BROPIRIMINE; DOXORUBICIN; EPIRUBICIN; HEMOCYANIN; INTERFERON; MITOMYCIN C; THIOTEPA;

ALLERGIC REACTION; BCG VACCINATION; BLADDER CANCER; BLADDER TUMOR; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CARCINOMA IN SITU; CHEMICAL CYSTITIS; DRUG EFFICACY; FEVER; FOLLOW UP; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIDE EFFECT; TRANSURETHRAL RESECTION; TUMOR GROWTH; TUMOR RECURRENCE;

EID: 0032446397     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.1998.tb00404.x     Document Type: Review

References (101)

1. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, Hawkins IR. Superficial bladder cancer: progression and recurrence. J Urol 1983;130:1083-1086.
2. Ahn HJ, Lee C. Bladder tumor: 20 years experience. Korean J Urol 1986;27:451-457.
3. Lamm DL, van der Meijden APM, Akaza H. Chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitation and uses? Int J Urol 1995;2(suppl 2):23-33.
4. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. Treated natural history of high risk superficial bladder cancer: 15 year outcome. J Urol 1997;158: 62-67.
5. Herr HW. Bladder cancer: natural history and implications for urothelial cancer prevention. J Cell Biol Chem 1992;161:112-119.
6. Hermann GG, Horn T, Steven K. The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer. J Urol 1998;159:91-94.
7. Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WF Jr. Superficial bladder cancer treated with BCG: a multivariate analysis of factors affecting tumor progression. J Urol 1989;141:22-29.
8. Reading J, Hall RR, Parmar MK. The application of a prognostic factor analysis for Ta. T1 bladder cancer in routine urological practice. Br J Urol 1995;75:604-607.
9. Holmang S, Hedelin H, Anderstrom C, Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 1995;153:1823-1826.
10. Torti FM, Lum BL, Aston D, MacKenzie N, Faysel M, Shortliffe LD, Freiha F. Superficial bladder cancer: the primacy of grade in the development of invasive disease. J Clin Oncol 1987;5:125-130.
11. Thompson RA Jr, Campbell EW Jr, Kramer HC, Jacobs SC, Naslund MJ. Late invasive recurrence despite long-term surveillance for superficial bladder cancer. J Urol 1993;149:1010-1011.
12. Herr HW, Wartinger DD. BCG therapy for superficial bladder cancer. A 10-year follow-up. J Urol 1992;149: 1020-1023.
13. Kurth KH, Denis L, Bouffioux C, Sylvester R, Debruyne FM, Pavone-Macaluso M, Oosterlinck W. Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 1995;31:1840-1846.
14. Lee E, Lee CK, Lee C. Prognostic factors in superficial bladder tumor. Korean J Urol 1990;31:795-801.
15. Kim HH, Lee C. T1 bladder tumor: a heterogenous and potentially dangerous group. J Korean Cancer Assn 1991; 23:843-851.
16. Asakura T, Takano Y, Iki M, Suwa Y, Noguchi S, Kubota Y, Masuda M. Prognostic value of Ki-67 for recurrence and progression of superficial bladder cancer. J Urol 1997;158:385-388.
17. Shin KY, Kong G, Kim WS, Lee TY, Woo YN, Lee JD. Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers. Br J Cancer 1997;75:1788-1792.
18. Tetu B, Allard P, Fradet Y, Roberge N, Bernard P. Prognostic significance of nuclear DNA content and S-phase fraction by flow cytometry in primary papillary superficial bladder cancer. Hum Pathol 1996;27:922-926.
19. Serth J, Kuczyk MA, Bokemeyer C, Hervatin C, Nafe R, Tan HK, Jonas U. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 1995;71:201-205.
20. Cordon-Cardo C, Zhang ZF, Dalbagni G, Drobnjak M, Charytonowicz E, Hu SX, Xu HJ, Reuter VE, Benedict WF. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 1997;57: 1217-1221.
21. Mizutani Y, Okada Y, Yoshida O. Expression of platelet-derived endothelial cell growth factor in bladder carcinoma. Cancer 1997;79:1190-1194.
22. Filella X, Menendez V, Molina R, Alcover J, Carretero P, Ballesta AM. TPA prognostic value in superficial bladder cancer. Anticancer Res 1996;16:2173-2175.
23. Crew JP, O'Brien T, Bradburn M, Fuggle S, Bicknell R, Cranston D, Harris AL. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997;57:5281-5285.
24. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, Herr HW, Reuter VE. Nuclear overexpression of small p53 protein in transitional bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993;85:53-59.
25. Lee E, Park I, Lee C. Prognostic markers of intravesical bacillus Calmette-Guérin therapy for multiple, high-grade, stage T1 bladder cancers. Int J Urol 1997;4:552-556.
26. Anderstrom C, Johansson S, Nilsson S. The significance of lamina propria invasion on the prognosis of patients with bladder tumors. J Urol 1980;124:23-26.
27. Pawinski A, Sylvester R, Kurth KH, Bouffioux C, van der Meijden A, Parmar MK, Bijnens L. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 1996;156:1934-1940.
28. Tolley DA, Parmar MK, Grigor KM, Lallemand G, Benyon LL, Fellows J, Freedman LS, Grigor KM, Hall RR, Hargreave TB, Munson K, Newling DW, Richards B, Robinson MR, Rose MB, Smith PH, Williams JL, Whelan P. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 1996;155: 1233-1238.
29. Krege S, Giani G, Meyer R, Otto T, Rubben H. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guérin. Participating clinics. J Urol 1996;156:962-966.
30. Lundholm C, Norlen BJ, Ekman P, Jahnson S, Lagerkvist M, Lindeborg T, Olsson JL, Tveter K, Wijkstrom H, Westberg R, Malmstrom PU. A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 1996;156:372-376.
31. Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WF Jr. Superficial bladder cancer treatment with BCG: a multivariate analysis of factors affecting tumor progression. J Urol 1989;141:22-29.
32. Herr HW. Progression of stage T1 bladder tumors after intravesical BCG. J Urol 1991;145:40-44.
33. Lebret T, Becette V, Barbagelatta M, Herve JM, Gaudez F, Barre P, Lugagne PM, Botto H. Correlation between p53 over-expression and response to bacillus Calmette-Guerin therapy in a high risk select population of patients with T1G3 bladder cancer. J Urol 1998;159:788-791.
34. Lacombe L, Dalbagni G, Zhang ZF, Cordon-Cardo C, Fair WR, Herr HW, Reuter VE. Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after BCG therapy: correlation to clinical outcome. J Clin Oncol 1996;14:2646-2652.
35. Richie JP. Intravesical chemotherapy, treatment selection, techniques, and results. Urol Clin North Am 1992;19:521-527.
36. Schulman CC, Robinson M, Denis L, Smith P, Viggiano G, de Pauw M, Dalesio O, Sylvester R. Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone. Eur Urol 1982;8:207-212.
37. Zincke H, Utz DC, Taylor WF, Myers RP, Leary FJ. Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. J Urol 1983;129:505-509.
38. Prout GR Jr, Koontz WW Jr, Coombs LJ, Hawkins IR, Friedell GH. Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa. J Urol 1983;130:677-680.
39. Medical Research Council. The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. MRC Working Party on Urological Cancer. Br J Urol 1985;57:680-685.
40. Hirao Y, Okajima E, Ozono S, Samma S, Sasaki K, Hiramatsu T, Babaya K, Watanabe S, Maruyama Y. A prospective randomized study of prophylaxis of tumor recurrence following transurethral resection of superficial bladder cancer - intravesical thio-TEPA versus oral UFT. Cancer Chemother Pharmacol 1992;30(suppl):26-30.
41. Abrams PH, Choa RG, Gaches CG, Ashken MH, Green NA. A controlled trial of single dose intravesical adriamycin in superficial bladder tumours. Br J Urol 1981;53:585-587.
42. NiijimaT, Koiso K, Akaza H. Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer. Cancer Chemother Pharmacol 1983;11(suppl):79-82.
43. Akaza H, Isaka S, Koiso K, KotakeT, Machida T, Maru A, Matsumura Y, Niijima T, Obata K, Ohe H. Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer. Prospective, randomized, controlled studies of the Japanese Urological Cancer Research Group. Cancer Chemother Pharmacol 1987;20(suppl):91-96.
44. Rubben H, Lutzeyer W, Fischer N, Deutz F, Lagrange W, Giani G. Natural history and treatment of low and high risk superficial bladder tumors. J Urol 1988;139:283-285.
45. Kim HH, Lee C. Intravesical mitomycin C instillation as a prophylactic treatment of superficial bladder tumor. J Urol 1989;141:1337-1340.
46. Oosterlinck W, Kurth KH, Schroder F, Bultinck J, Hammond B, Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. Urology 1993;149:749-752.
47. Melekos MD. Prophylaxis of superficial bladder cancer with a modified intravesical epirubicin treatment schedule. Oncology 1993;50:450-455.
48. Igawa M, Urakami S, Shirakawa H, Shiina H, Ishibe T, Kadena H, Usui T, Kawanishi M. Intravesical instillation of epirubicin: effect on tumour recurrence in patients with dysplastic epithelium after transurethral resection of superficial bladder tumour. Br J Urol 1996;77:358-362.
49. Bouffioux C, Kurth KH, Bono A, Oosterlinck W, Kruger CB, De Pauw M, Sylvester R. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 1995;153:934-941.
50. Lamm DL, Riggs DR, Traynelis CL, Nseyo UO. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 1995;153: 1444-1450.
51. Prout GR Jr, Koontz WW Jr, Coombs LJ, Hawkins IR, Friedell GH. Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa. J Urol 1983;130:677-680.
52. Green DF, Robinson MR, Glashan R, Newling D, Dalesio O, Smith PH. Does intravesical chemotherapy prevent invasive bladder cancer? J Urol 1984;131:33-35.
53. Kurth KH, Sylvester R, de Pauw M, TenKate F. Intracavitary treatment of transitional cell carcinoma of the bladder: questions and lessens after 27 years of experience. In: Debruyne FMJ, Denis L, van der Meijden APM (eds) EORTC genitourinary group monograph 6: BCG in superficial bladder cancer. New York: Alan R Liss, 1989:125-145.
54. Huland H, Otto U, Droese M, Kloppel G. Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival. J Urol 1984;132:27-29.
55. Tolley DA, Hargreave TB, Smith PH, Williams JL, Grigor KM, Parmar MK, Freedman LS, Uscinska BM. Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br Med J 1988;296:1759-1761.
56. Lamm DL. BCG in perspective: advances in the treatment of superficial bladder cancer. Eur Urol 1995;27(suppl 1):2-8.
57. Lamm DL. Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol 1985;134:40-47.
58. Herr HW, Pinsky CM, Whitmore WF Jr, Sogani PG, Oettgen HF, Melamed MR. Experience with intravesical bacillus Calmette-Guerin therapy of superficial bladder tumors. Urology 1985;25:119-123.
59. Melekos MD. Intravesical bacillus Calmette-Guérin prophylactic treatment for superficial bladder tumors: results of a controlled prospective study. Urol Int 1990;45: 137-141.
60. Pagano F, Bassi P, Milani C, Meneghini A, Maruzzi D, Garbeglio A. A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer: is it effective? J Urol 1991;146:32-35.
61. Park MS, Lee C. Bacillus Calmette-Guerin instillation as a prophylactic treatment of superficial bladder tumor. Korean J Urol 1990;31:52-58.
62. Kim HG, Kim HH, Lee E, Lee C. Prophylactic efficacy of intravesical bacillus Calmette-Guérin for high risk superficial bladder tumor. Korean J Urol 1994;35:1186-1192.
63. Melekos MD, Zarakovitis IE, Fokaefs ED, Dandinis K, Chionis H, Bouropoulos C, Dauaher H. Intravesical bacillus Calmette-Guérin versus epirubicin in the prophylaxis of recurrent and/or multiple superficial bladder tumours. Oncology 1996;53:281-288.
64. Martinez-Pineiro JA, Jimenez Leon J, Martinez-Pineiro L Jr, Fiter L, Mosteiro JA, Navarro J, Garcia Matres MJ, Carcamo P. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol 1990;143:502-506
65. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA Jr, Sullivan J, Sarosdy MF. A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Guérin for transitional cell carcinoma of the bladder. New Engl J Med 1991;325:1205-1209.
66. Lamm DL. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 1992;19:573-580.
67. Herr HW, Schwalb DM, Zhang ZF, Sogani PC, Fair WR, Whitmore WF Jr, Oettgen HF. Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol 1995;13: 1404-1408.
68. Lee E, Park MS, Lee C. Mitomycin C vs bacillus Calmette-Guerin: comparison of prophylactic efficacy to high risk superficial bladder tumor. J Korean Cancer Assoc 1991;23:101-106.
69. Brosman SA. Experience with bacillus Calmette-Guérin in patients with superficial bladder carcinoma. J Urol 1982;128:27-30.
70. Debruyne FM, van der Meijden AP, Geboers AD, Franssen MP, van Leeuwen MJ, Steerenberg PA, de Jong WH, Ruitenberg JJ. BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. First results of randomized prospective trial. Urology 1988; 31(suppl):20-25.
71. Witjes JA, van der Meijden AP, Witjes WP, Doesburg W, Schaafsma HE, Debruyne FM. A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group. Eur J Cancer 1993;29A:1672-1676.
72. Lee E, Kim HH, Min KJ, Lee C. A comparison of mitomycin C and bacillus Calmette-Guérin for the prophylaxis of high risk superficial bladder tumor. Korean J Urol 1992;33:1014-1019.
73. Schellhammer PF, Ladaga LE, Moriarty RP. Intravesical bacillus Calmette-Guerin for the treatment of superficial transitional cell carcinoma of the prostatic urethra in association with carcinoma of the bladder. J Urol 1995;153:53-56.
74. Luftenegger W, Ackermann DK, Futterlieb A, Kraft R, Minder CE, Nadelhaft P, Studer UE. Intravesical versus intravesical plus intradermal bacillus Calmette-Guérin: a prospective randomized study in patients with recurrent superficial bladder tumors. J Urol 1996;155:483-487.
75. Kelley DR, Ratliff TL, Catalona WJ, Shapiro A, Lage JM, Bauer WC, Haaff EO, Dresner SM. Intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results. J Urol 1985;134:48-53.
76. Coplen DE, Marcus MD, Myers JA, Ratliff TL, Catalona WJ. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guérin: analysis of possible predictors of response free of tumor. J Urol 1990;144:652-657.
77. Catalona WJ, Hudson MA, Gillen DP, Andriole GL, Ratliff TL. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 1987;137:220-224.
78. Hudson MA, Ratliff TL, Gillen DP, Haaff EO, Dresner SM, Catalona WJ. Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial. J Urol 1987;138: 295-298.
79. Martinez-Pineiro JA, Solsona H, Flores N, Isoma S. Improving the safety of BCG immunotherapy by dose reduction. Cooperative Group CUETO. Eur Urol 1995; 27(suppl 1):13-18.
80. Hurle R, Losa A, Ranieri A, Graziotti P, Lembo A. Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy. J Urol 1996;156: 1602-1605.
81. Mack D, Frick J. Five-year results of a phase II study with low-dose bacillus Calmette-Guérin therapy in high-risk superficial bladder cancer. Urology 1995;45:958-961.
82. Lamm DL. Complications of bacillus Calmette-Guérin immunotherapy. Urol Clin North Am 1992;19:565-572.
83. Schnapp DS, Weiss GH, Smith AD. Fever following intracavitary bacillus Calmette-Guerin therapy for upper tract transitional cell carcinoma. J Urol 1996;156:386-388.
84. Torti FM, Shortliffe LD, Williams RD, Puts WC, Kempson RL, Ross JC, Palmer J, Meyers F, Ferrari M, Hannigan J. Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group study. J Clin Oncol 1988;6:476-483.
85. Belldegrun AS, Franklin JR, O'Donnell MA, Gomella LG, Klein E, Neri R, Nseyo UO, Ratliff TL, Williams RD. Superficial bladder cancer: the role of interferon-alpha. J Urol 1998;159:1793-1801.
86. Jimenez-Cruz JF, Vera-Donoso CD, Leiva O, Pamplona M, Rioja-Sanz LA, Martinez-Lasierra M, Flores N, Unda M. Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacillus Calmette-Guérin and interferon-alpha. Urology 1997;50:529-535.
87. Boccardo F, Cannata D, Rubagotti A, Guarneri D, Decensi A, Canobbio L, Curotto A, Martorana G, Pegoraro C, Selvaggi F. Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results ofa multicentric Italian study. J Clin Oncol 1994;12:7-13.
88. Raitanen MP, Lukkarinen O. A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Finnish Multicentre Study Group. Br J Urol 1995;76:697-701.
89. Pryor K, Stricker P, Russell P, Golovsky D, Penny R. Antiproliferative effects of bacillus Calmette-Guérin and interferon alpha 2b on human bladder cancer cells in vitro. Cancer Immunol Immunother 1995;41:309-316.
90. Stricker P, Pryor K, Nicholson T, Goldstein D, Golovsky D, Ferguson R, Nash P, Ehsman S, Rumma J, Mammen G, Penny R. Bacillus Calmette-Guérin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Urology 1996;48:957-961.
91. Rintala E, Jauhiainen K, Kaasinen E, Nurmi M, Alfthan O. Alternating mitomycin C and bacillus Calmette-Guérin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. Finnbladder Group. J Urol 1996;156:56-59.
92. Sarosdy MF, Lamm DL, Williams RD, Moon TD, Flanigan RC, Crawford ED, Wilks NE, Earhart RH, Merritt JA. Phase 1 trial of oral bropirimine in superficial bladder cancer. J Urol 1992;147:31-33.
93. Witjes JA. Treatment of carcinoma in situ of the urinary bladder with bropirimine. Eur Urol 1997;31(suppl 1):27-30.
94. Sarosdy MF. A review of clinical studies of bropirimine immunotherapy of carcinoma in situ of the bladder and upper urinary tract. Eur Urol 1997;31(suppl 1):20-26.
95. Wishahi MM, Ismail IM, Ruebben H, Otto T. Keyholelimpet hemocyanin immunotherapy in the bilharzial bladder: a new treatment modality? Phase II trial: superficial bladder cancer. J Urol 1995;153:926-928.
96. Flamm J, Bucher A, Holtl W, Albrecht W. Recurrent superficial transitional cell carcinoma of the bladder: adjuvant topical chemotherapy versus immunotherapy. A prospective randomized trial. J Urol 1990;144:260-263.
97. Aso Y, Akaza H, Kotake T, Tsukamoto T, Imai K, Naito S. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group. Eur Urol 1995;27: 104-109.
98. Nseyo UO. Photodynamic study. Urol Clin North Am 1992;19:591-599.
99. Herman JR, Lerner SP. Current status of gene therapy for prostate and bladder cancer. Int J Urol 1997;4:435-440.
100. Theuer CP, FitzGerald DJ, Pastan I. A recombinant form of Pseudomonas exotoxin A containing transforming growth factor alpha near its carboxyl terminus for the treatment of bladder cancer. J Urol 1993;149:1626-1632.
101. Lee E, Jeong H, Yoon SJ, Lee HW, Min KJ, Choi YK, Lee C. Change of cellular immunity and T cell subset of mouse immunocytes activated by fractionated bacillus Calmette-Guerin. Korean J Urol 1998;39:423-430.